financetom
Business
financetom
/
Business
/
Yum Brands beats Q3 profit estimates, starts strategic review for Pizza Hut
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Yum Brands beats Q3 profit estimates, starts strategic review for Pizza Hut
Nov 4, 2025 4:25 AM

Overview

* Yum! Brands ( YUM ) Q3 adjusted EPS rose 15% yr/yr, beating analyst expectations

* Company initiates strategic review for Pizza Hut to maximize long-term value

* Worldwide system sales grew 5%, led by Taco Bell at 9% and KFC ( YUM ) at 6%

Outlook

* Company to complete acquisition of 128 Taco Bell restaurants in Q4

* Company targets 5% unit growth and 7% system sales growth long-term

Result Drivers

* TACO BELL GROWTH - Taco Bell led system sales growth with a 9% increase, driven by strong same-store sales and international expansion

* KFC EXPANSION - KFC's ( YUM ) unit growth of 6% was supported by opening 760 new restaurants across 60 countries

* DIGITAL SALES RECORD - Record digital sales reached $10 bln, with a 60% digital mix, contributing to overall sales growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $1.58 $1.48

Adjusted (26

EPS Analysts

)

Q3 EPS $1.41

Q3 KFC 44.60%

Operatin

g Margin

Q3 KFC $392 mln

Operatin

g Profit

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 11 "strong buy" or "buy", 21 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the restaurants & bars peer group is "buy."

* Wall Street's median 12-month price target for Yum! Brands Inc ( YUM ) is $160.00, about 12.9% above its November 3 closing price of $139.38

* The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 22 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Looking At Netflix's Recent Unusual Options Activity
Looking At Netflix's Recent Unusual Options Activity
Jun 17, 2024
Whales with a lot of money to spend have taken a noticeably bearish stance on Netflix ( NFLX ). Looking at options history for Netflix ( NFLX ) we detected 8 trades. If we consider the specifics of each trade, it is accurate to state that 25% of the investors opened trades with bullish expectations and 75% with bearish. From...
Limbach Holdings Insider Sold Shares Worth $399,494, According to a Recent SEC Filing
Limbach Holdings Insider Sold Shares Worth $399,494, According to a Recent SEC Filing
Jun 17, 2024
09:48 AM EDT, 06/17/2024 (MT Newswires) -- Joshua Horowitz, Director, on June 14, 2024, sold 7,000 shares in Limbach Holdings ( LMB ) for $399,494. Following the Form 4 filing with the SEC, Horowitz has control over a total of 290,587 shares of the company, with 40,915 shares held directly and 249,672 shares controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1606163/000110465924071887/xslF345X03/tm2417374-1_4seq1.xml Price: 53.91,...
Aerovate Therapeutics Plunges after Prospective Hypertension Medication Misses Targets in Phase 2 Study, Scraps More Testing
Aerovate Therapeutics Plunges after Prospective Hypertension Medication Misses Targets in Phase 2 Study, Scraps More Testing
Jun 17, 2024
09:50 AM EDT, 06/17/2024 (MT Newswires) -- Aerovate Therapeutics ( AVTE ) fell sharply in early trading on Monday, sinking over 90% after the company said its AV-101 drug candidate failed to reach its primary endpoint during phase 2b testing. The endpoint for the mid-stage trial of the inhaled form of Novartis' (NVO) iMatinib cancer medication as a prospective treatment...
Autodesk Shareholder Plans Lawsuit to Delay Annual Meeting, Reopen Nomination Window
Autodesk Shareholder Plans Lawsuit to Delay Annual Meeting, Reopen Nomination Window
Jun 17, 2024
09:48 AM EDT, 06/17/2024 (MT Newswires) -- Autodesk ( ADSK ) shareholder Starboard Value said Monday that it plans to sue Autodesk ( ADSK ) and its board for allegedly failing to disclose material accounting and disclosure issues. The lawsuit will seek to delay Autodesk's ( ADSK ) 2024 annual meeting, which is scheduled for July 16, and reopen the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved